Exact Sciences Corp (Put) (NASDAQ:EXAS) Shareholder Senzar Asset Management Llc Upped Position as Price Declined by $21.45 Million

May 17, 2018 - By Brian Ramirez

Exact Sciences Corporation (NASDAQ:EXAS) Corporate LogoDuring Q4 2017 the big money sentiment decreased to 0.88. That’s change of 0.13, from 2017Q3’s 1.01. 25 investors sold all, 105 reduced holdings as EXAS ratio fall. 70 increased stakes while 44 funds took stakes. Funds hold 92.48 million shares thus 1.24% less from 2017Q3’s 93.65 million shares. Salem Counselors reported 6,480 shs stake. Amalgamated National Bank & Trust stated it has 0.02% in Exact Sciences Corporation (NASDAQ:EXAS). Parallax Volatility Advisers Limited Partnership accumulated 0% or 17,892 shs. Rock Springs Mngmt L P holds 1.04% or 434,900 shs in its capital. Granahan Inv Management Inc Ma has invested 0.86% in Exact Sciences Corporation (NASDAQ:EXAS). Citigroup has 2.09 million shs. First Mercantile Tru has 0.33% invested in Exact Sciences Corporation (NASDAQ:EXAS). C M Bidwell And Associates Limited reported 2,230 shs stake. Amer Intll Grp Inc has invested 0.01% in Exact Sciences Corporation (NASDAQ:EXAS). Elk Creek Limited Liability Company has invested 1.79% in Exact Sciences Corporation (NASDAQ:EXAS). Envestnet Asset Management Incorporated invested in 0% or 2,725 shs. Putnam Investments Limited Liability Co invested in 0% or 38,121 shs. Federated Investors Inc Pa has 44,260 shs for 0.01% of their capital. Tudor Corp Et Al owns 5,357 shs. California Public Employees Retirement Systems reported 266,481 shs.

EXAS registered $25.11 million net activity with 0 buys and 21 insider sales since January 2, 2018. Shares for $1.11 million were sold by LIDGARD GRAHAM PETER on Friday, February 23. On Tuesday, April 10 $335,630 worth of stock was sold by Carey Thomas D.. $141,341 worth of Exact Sciences Corporation (NASDAQ:EXAS) was sold by COWARD D SCOTT. Shares for $381,447 were sold by WYZGA MICHAEL S. ARORA MANEESH had sold 12,352 shs worth $522,959. $126,925 worth of Exact Sciences Corporation (NASDAQ:EXAS) was sold by Doyle James Edward.

Based on the latest 2018Q1 report from the SEC, Senzar Asset Management Llc increased its stake in Exact Sciences Corp (Put) (NASDAQ:EXAS) by 9679.82%. Exact Sciences Corp (Put) (NASDAQ:EXAS) stock Sank 19.82% while Senzar Asset Management Llc bought 536,359 shares. Senzar Asset Management Llc is holding 541,900 shares, compared to 5,541 last quarter. The reported value is $21.86M. $6.21 billion is the market cap of Exact Sciences Corp (Put). EXAS touched $50.96 during the last trading session after $0.19 change.Currently Exact Sciences Corporation is uptrending after 81.43% change in last May 17, 2017. EXAS has 1.04 million shares volume. The stock outperformed the S&P 500 by 69.88%.

Senzar Asset Management Llc manages about $442.00M and $316.94 million US longs. It reduced its stake in Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) by 798,976 shares to 649,824 shares, valued at $10.03 million in 2018Q1, according to the report. It decreased Cvs Health Corp (NYSE:CVS) position by 194,670 shares to 120,830 shares, and cut its Sanofi (NYSE:SNY) stake.

Senzar Asset Management Llc is a New York-based hedge fund with more than $442.00 million AUM in December, 2014. Taken from Senzar Asset Management latest Adv, the fund reported to have 7 full and part-time employees. Among which 4 performing investment advisory and research functions. The hedge fund had between 1-10 clients.

Exact Sciences Corporation (NASDAQ:EXAS) Ratings Coverage

A total of 11 analysts rate Exact Sciences (NASDAQ:EXAS) as follows: 8 “Buy”, 3 “Hold” and 0 “Sell”. Тherefore 73% are bullish. (NASDAQ:EXAS) has 16 ratings reports on 17 May 2018 according to StockzIntelligence. On Wednesday, March 28 the firm earned “Buy” rating by Leerink Swann. On Thursday, March 29 the rating was maintained by William Blair with “Buy”. In Thursday, January 18 report Craig Hallum maintained the stock with “Buy” rating. On Friday, February 23 the firm has “Buy” rating given by Canaccord Genuity. The company rating was maintained by Canaccord Genuity on Friday, April 27. On Friday, February 23 Benchmark downgraded Exact Sciences Corporation (NASDAQ:EXAS) to “Hold” rating. On Tuesday, March 27 the firm has “Buy” rating by Jefferies given. On Monday, March 19 the firm has “Buy” rating given by Canaccord Genuity. The stock rating was upgraded by BTIG Research to “Buy” on Tuesday, April 3. On Wednesday, January 17 the stock of Exact Sciences Corporation (NASDAQ:EXAS) has “Buy” rating given by Benchmark.

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States.The company has $6.21 billion market cap. The firm develops the Cologuard, a non-invasive stool DNA screening test for the early detection of colorectal cancer and pre-cancer.Last it reported negative earnings. It has a collaboration, license, and purchase agreement with Genzyme Corporation; and license agreement with MAYO Foundation for Medical Education and Research.

Exact Sciences Corporation (NASDAQ:EXAS) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: